Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ApexOnco Front Page
Recent articles
What similarly acting projects are still unpartnered?
The sale of remaining rights to Allogene ends acrimony between the two companies.
ASCO is fast approaching, but in the meantime Olema will have an important readout.
The company dribbles out more data on IMA203, and the numbers head in the right direction.
Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.
Keyvibe-010 fails, but not for the reason you might have expected.
Tamarack data reveal vobra-duo’s toxicity, and wipe out the past six months’ share price gains.
